Research News
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/NatlMGAwarenessMonthLeadart_0.jpg)
June 16, 2010
In recognition of June being National Myasthenia Gravis Awareness Month, Quest News Online is examining the disease from several perspectives. This article offers an overview of signs, symptoms,
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/light_switch_lead_0.jpg)
June 15, 2010
Neuraltus Pharmaceuticals of Palo Alto, Calif., is developing a small molecule whose target is regulation of immune system cells believed to contribute to neuroinflammation and disease progression in
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/IV%20bag%20closeup.jpg)
June 11, 2010
A 600-person trial of intravenous ceftriaxone, an antibiotic in the cephalosporin family that's approved to treat certain types of infections, is still looking for participants at 53 sites in the
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/mouse-testing-leadart.jpg)
June 09, 2010
Scientists in the United Kingdom have found that mice carrying a genetic mutation that causes oculpharyngeal muscular dystrophy (OPMD) in humans and showing a disease resembling human OPMD benefited
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/DNA%20syringe%2C%20version%202.jpg)
June 02, 2010
The biopharmaceutical company AVI BioPharma has announced additional encouraging results from its clinical trial of AVI4658, an experimental treatment for Duchenne muscular dystrophy (DMD).
The new
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/als%20tdi%20changes%20lead%20art.jpg)
June 01, 2010
In its quarterly Research Update Webcast on May 18, 2010, the ALS Therapy Development Institute (ALS TDI) informed viewers of a "paradigm shift" in TDI research. The changes include the addition of
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/strike%20out%20baseball.JPG)
May 28, 2010
Idebenone, a substance believed to act as an antioxidant and to aid in energy production in cellular structures called mitochondria, has failed to benefit people with Friedreich's ataxia (FA) in a
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/MP3%20with%20earphone%20wire.jpg)
May 24, 2010
Scientists at the Neuromuscular Disorders Program at Nationwide Children’s Hospital in Columbus, Ohio, are producing a series of podcasts examining current research in neuromuscular disease.
The
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/DNA-syringe-2.JPG)
May 21, 2010
Scientists at five U.S. institutions have successfully used gene therapy to improve muscle function in a single human subject with a hereditary form of inclusion-body myositis (IBM) caused by
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/apples%20and%20orange2_0.jpg)
May 19, 2010
Scientists at Northwestern University Feinberg School of Medicine in Chicago have announced new findings showing some forms of familial and nonfamilial ("sporadic") amyotrophic lateral sclerosis (ALS
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/MRI%20machine%20copy.jpg)
May 17, 2010
The use of magnetic resonance imaging (MRI) as an assessment tool in boys with Duchenne muscular dystrophy (DMD) is being studied by former MDA grantee Krista Vandenborne, through a $7.5 million
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/key%20in%20lock.jpg)
May 05, 2010
MDA-supported researchers at 4s3 Bioscience, a biotechnology company in Medford, Mass., are using a new molecular strategy to transport a potentially therapeutic protein into muscles, as an
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/CMT%20kid%2C%20Michael%20Shy.jpg)
April 23, 2010
Two scales that can be used to assess disease progression and any response that may occur to a treatment have been developed for children with Charcot-Marie-Tooth (CMT) disease.
One, called the CMT
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/tumeric%20powder.jpg)
April 21, 2010
Mice with a genetic mutation in the myelin protein zero (MPZ) gene, which develop a disease resembling human type 1B Charcot-Marie-Tooth disease (CMT1B), benefited from treatment with curcumin and
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/injection%20syringe%20in%20gloved%20hand.jpg)
April 21, 2010
Mice with a disorder resembling type 1A Charcot-Marie-Tooth (CMT1A) disease that received a single intramuscular injection of genes for the protein neurotrophin 3 (NT3) showed improvements in grip
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/yellowcautionlight2.jpg)
April 21, 2010
Unwanted responses by the immune system to dystrophin have been seen in a small, MDA-supported clinical trial of gene therapy for Duchenne muscular dystrophy (DMD)— an unexpected finding,
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/closer-look-chart-magnifying-glass2.jpg)
April 19, 2010
PTC Therapeutics, a South Plainfield, N.J., biopharmaceutical company, has announced findings that reflect the company's closer look at a large-scale trial of its experimental drug ataluren.
The
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/Fish%2C%20lure%20LeadArt.JPG)
April 16, 2010
ACE031, a laboratory-modified protein developed by Acceleron Pharma of Cambridge, Mass., has shown promise as a therapy to increase muscle mass, based on results of a trial in healthy volunteers. The
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/mouse%20and%20nanoparticle%20LeadArt.jpg)
April 15, 2010
A research group from the University of Sheffield in the United Kingdom has found that mice with a disease mimicking human spinal muscular atrophy (SMA) benefited significantly from intravenous
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/Research%20generic%20Leadart%203.jpg)
April 15, 2010
AVI4658, an experimental treatment for patients with Duchenne muscular dystrophy (DMD) caused by certain mutations in the gene for the muscle protein dystrophin, has shown promising results when
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/organization%20chart%20Lead%20Art.jpg)
April 15, 2010
Editor's note:This story was updated Feb. 4, 2011, to reflect the availability of a paper and editorial on this subject in Annals of Neurology.
Results of genetic testing done at Wayne State
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/periodic%20paralysis%20qno%20lead%20art_0.jpg)
April 13, 2010
The multinational pharmaceutical company GlaxoSmithKline (GSK) and the Dutch biotechnology company Prosensa announced "intriguing results" following a 12-person trial of an experimental "exon
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/syringe%2C%20vial.jpg)
April 13, 2010
Results of the MDA-supported trial of gentamicin in Duchenne muscular dystrophy (DMD) were presented Wednesday, April 14, at the annual meeting of the American Academy of Neurology (AAN), held in
![[title]](http://quest.mda.org/sites/default/files/imagecache/mda_org_frontpage100x75/yes%20no%20check%20boxes_0.jpg)
April 12, 2010
An MDA-supported, 10-center trial of more than 100 people with amyotrophic lateral sclerosis (ALS) who took the oral medication lithium carbonate — some in conjunction with the ALS drug riluzole —
![[title]](http://alsn.mda.org/files/alsn/imagecache/175xFrontFeature/theater%20masks%2C%20emotions.jpg)
April 12, 2010
The experimental drug Zenvia, developed by Avanir Pharmaceuticals as a treatment for unwanted laughing/crying spells in ALS, has shown continued promise in lessening the frequency of such episodes
Pages
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc. All rights reserved.
